The majority (90%) of neurologists were aware of 40 out of 61 recommendations on the treatment of myasthenia gravis (MG). Most Spanish neurologists know, agree on, and apply guidelines for the ...

Intercept Pharmaceuticals, the developer of the PBC drug, suggested that the company's view on the drug's benefit and risk profile differed from that of the US Food and Drug Administration.

Derived thresholds of 4.5 kg for deterioration, 5 kg for improvement, and 20% for either deterioration or improvement are significantly more specific and accurate. More stringent thresholds than what ...

CLL-related immune dysfunction, along with therapy-associated immunosuppression, contributes to impaired tumor surveillance. Patients with chronic lymphocytic leukemia (CLL) are at increased risk for ...

Immunohistochemistry can identify concomitant SM in acute myeloid leukemia, leading to better risk stratification and management. The most common forms of AML in pediatric patients are those ...

The efficacy of taladegib in IPF will be evaluated at a range of doses over 24 weeks in the phase 2 WHISTLE-PF study. Endeavor BioMedicines has announced that the United States Food and Drug ...

Intravenous immunoglobulin-induced thrombocytopenia was reported in 146 cases, with the highest incidence seen in patients with immune-mediated skin diseases. Intravenous immunoglobulin (IVIg) therapy ...

CSL will commercially launch garadacimab-gxii in the United States immediately, with product availability before the end of June 2025. Garadacimab-gxii (Andembry ®), a novel monoclonal antibody ...

Kerrie Walters, who has MS, and her service dog, Wooldridge, at home in Grants Pass, Oregon (Credit: Jennifer Butler Photography) Kerrie Walters first heard of PoNS in a chance encounter with TV ...

A patient with distal acquired demyelinating symmetric neuropathy (DADS) deteriorated and presented with chronic inflammatory demyelinating polyneuropathy (CIDP)-like symptoms after treatment with ...

No significant association was observed between statin use and adverse effects of grade 3 or higher. Statin use was significantly associated with improved survival outcomes in patients with chronic ...

In CIDP, SOC therapies (immunoglobulins/corticosteroids) are burdensome, have variable efficacy, and significant side-effects. Two phase 3 clinical trials, MOBILIZE ...